杰克说药 | GPP治疗新突破：佩索利单抗与IL-36靶点的未来
Spesolimab的获批，代表IL-36靶点在抗体类型药物的突破。
Time：
2023-06-27 11:40
Author：
李杰教授
尘埃落定！FDA再次拒绝批准奥贝胆酸，Intercept将终止NASH领域投资
奥贝胆酸的折戟与落寞，对于NASH药物赛道来说，或许仅仅是一个开始。
Time：
2023-06-23 14:11
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务